Medite Cancer Diagnostics, Inc.
MDIT
$0.00
$0.00-98.00%
OTC PK
| 09/30/2018 | 06/30/2018 | 03/31/2018 | 12/31/2017 | 09/30/2017 | |
|---|---|---|---|---|---|
| Revenue | 2.39M | 2.28M | 1.51M | 1.96M | 1.69M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.39M | 2.28M | 1.51M | 1.96M | 1.69M |
| Cost of Revenue | 925.00K | 1.22M | 1.17M | 2.90M | 1.32M |
| Gross Profit | 1.47M | 1.06M | 335.00K | -936.00K | 369.00K |
| SG&A Expenses | 1.36M | 762.00K | 919.00K | 2.02M | 1.25M |
| Depreciation & Amortization | 62.00K | 68.00K | 71.00K | 80.00K | 110.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.49M | 2.30M | 2.47M | 5.01M | 3.10M |
| Operating Income | -95.00K | -28.00K | -960.00K | -3.05M | -1.41M |
| Income Before Tax | -735.00K | -559.00K | -1.40M | -3.12M | -1.61M |
| Income Tax Expenses | -- | 4.00K | -- | -491.00K | -- |
| Earnings from Continuing Operations | -735.00K | -563.00K | -1.40M | -2.63M | -1.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -735.00K | -563.00K | -1.40M | -2.63M | -1.61M |
| EBIT | -95.00K | -28.00K | -960.00K | -3.05M | -1.41M |
| EBITDA | -33.00K | 40.00K | -889.00K | -2.97M | -1.30M |
| EPS Basic | -0.01 | -0.01 | -0.04 | -0.09 | -0.06 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.02 | -0.07 | -0.04 |
| EPS Diluted | -0.01 | -0.01 | -0.04 | -0.09 | -0.06 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.02 | -0.07 | -0.04 |
| Average Basic Shares Outstanding | 72.37M | 55.47M | 39.17M | 29.58M | 27.70M |
| Average Diluted Shares Outstanding | 72.37M | 55.47M | 39.17M | 29.58M | 27.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |